Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA-based in vivo CAR-T candidate targeting CD19. The results were presented in an oral session by Dr. Pin Wang, Chief Scientific Officer of Grit […]

New York, New York–(Newsfile Corp. – December 6, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADS” or “ADSs”) of WPP plc (NYSE: WPP) between February 27, 2025 and July 8, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single infusion as early as second line Data suggest stronger immune fitness in earlier lines may be associated with longer progression free survival Johnson & Johnson(NYSE: JNJ) announced today updated results from the Phase 3 CARTITUDE-4

(NASDAQ:COGT), — Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline — — Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time this has been shown in NonAdvSM patients —

(NasdaqGM:NRIX), Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data from randomized Phase 1b cohorts points to higher ORR and longer progression free survival at the 600 mg recommended Phase 2 dose

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) GlobeNewswire December 06, 2025 — Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition GlobeNewswire December 06, 2025 Objective response rate (ORR) of 83% including two complete responses in CLL patients

500 changemakers from over 50 countries stand in solidarity with Hong Kong and co-create paths forward through education The Yidan Prize Foundation, the Hong Kong-based global philanthropic foundation, convened over 500 educators, youth, and NGO leaders from over 50 countries across six continents for its annual flagship Yidan Prize Summit. In remembrance of those who

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Blue Owl (OWL) To Contact Him Directly To Discuss Their Options If you purchased or acquired Blue Owl securities between February 6, 2025 and November 16, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire

BLUE OWL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Blue Owl Capital, Inc. and Encourages Investors to Contact the Firm GlobeNewswire December 06, 2025 Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Blue Owl (OWL) To Contact Him Directly